| Literature DB >> 22303486 |
Ching-Lan Wu1, Jau-Ching Wu, Wen-Cheng Huang, Hung-Ta H Wu, Hong-Jen Chiou, Laura Liu, Yu-Chun Chen, Tzeng-Ji Chen, Henrich Cheng, Cheng-Yen Chang.
Abstract
PURPOSE: To investigate the incidence and risk of stroke after percutaneous vertebroplasty in patients with osteoporosis.Entities:
Mesh:
Year: 2012 PMID: 22303486 PMCID: PMC3269435 DOI: 10.1371/journal.pone.0031405
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow of data processing.
From an osteoporotic cohort of 58,703 patients in a nationwide representative cohort of one million people, 421 patients had percutaneous vertebroplasty (vertebroplasty group; n = 421), while age-, sex- and propensity score-matched patients comprised the comparison group (n = 1,655). The two groups were compared and followed-up for up to five years for subsequent stroke events.
Comparison for demographics and socio-economic status (n = 1989).
| Comparison group | Vertebroplasty group | ||||
| n = 1655 | (%) | n = 334 | (%) |
| |
| Gender | 0.975 | ||||
| Female | 1292 | (78.1) | 261 | (78.1) | |
| Male | 363 | (21.9) | 73 | (21.9) | |
| Age, Mean (SD) | 75.1 | (9.0) | 75.0 | (9.3) | 0.859 |
| Demographic characteristics | |||||
| Insurance levels (NTD$) | 0.427 | ||||
| 40,000- | 20 | (1.2) | 2 | (.6) | |
| 20,000–39,999 | 625 | (37.8) | 139 | (41.6) | |
| 1–19,999 | 382 | (23.1) | 69 | (20.7) | |
| Dependent | 628 | (37.9) | 124 | (37.1) | |
| Geographic locations | 0.065 | ||||
| Northern area | 712 | (43.0) | 165 | (49.4) | |
| Central area | 306 | (18.5) | 44 | (13.2) | |
| Southern area | 587 | (35.5) | 114 | (34.1) | |
| Eastern area | 50 | (3.0) | 11 | (3.3) | |
| Urbanization levels | 0.435 | ||||
| 1 (most urbanization) | 407 | (24.6) | 71 | (21.3) | |
| 2 | 409 | (24.7) | 75 | (22.5) | |
| 3 | 235 | (14.2) | 54 | (16.2) | |
| 4 | 294 | (17.8) | 68 | (20.4) | |
| 5 (least urbanization) | 310 | (18.7) | 66 | (19.8) | |
Comparison of co-morbidities (n = 1989).
| Comparison group | Vertebroplasty group | ||||
| n = 1655 | (%) | n = 334 | (%) |
| |
|
| |||||
| Hypertension | 0.413 | ||||
| Yes | 1157 | (69.9) | 241 | (72.2) | |
| No | 498 | (30.1) | 93 | (27.8) | |
| Diabetes | 0.609 | ||||
| Yes | 679 | (41.0) | 132 | (39.5) | |
| No | 976 | (59.0) | 202 | (60.5) | |
| Dyslipidemia | 0.964 | ||||
| Yes | 800 | (48.3) | 161 | (48.2) | |
| No | 855 | (51.7) | 173 | (51.8) | |
| COPD | 0.288 | ||||
| Yes | 874 | (52.8) | 187 | (56.0) | |
| No | 781 | (47.2) | 147 | (44.0) | |
| Chronic renal failure | 0.659 | ||||
| Yes | 141 | (8.5) | 26 | (7.8) | |
| No | 1514 | (91.5) | 308 | (92.2) | |
| Parkinson's disease | 0.163 | ||||
| Yes | 62 | (3.7) | 18 | (5.4) | |
| No | 1593 | (96.3) | 316 | (94.6) | |
| Charlson's comorbidity index, Mean (SD) | 4.01 | (2.7) | 4.16 | (2.8) | 0.358 |
|
| |||||
| Inflammatory spondylopathies | 0.991 | ||||
| Yes | 10 | (.6) | 2 | (.6) | |
| No | 1645 | (99.4) | 332 | (99.4) | |
| Spondylosis | 0.747 | ||||
| Yes | 224 | (13.5) | 43 | (12.9) | |
| No | 1431 | (86.5) | 291 | (87.1) | |
| Spondylolisthesis | 0.194 | ||||
| Yes | 182 | (11.0) | 45 | (13.5) | |
| No | 1473 | (89.0) | 289 | (86.5) | |
| Spinal stenosis | 0.009 | ||||
| Yes | 251 | (15.2) | 70 | (21.0) | |
| No | 1404 | (84.8) | 264 | (79.0) | |
| Intervertebral disc disorders | 0.462 | ||||
| Yes | 199 | (12.0) | 45 | (13.5) | |
| No | 1456 | (88.0) | 289 | (86.5) | |
| Propensity score, Mean (SD) | 0.56 | (0.2) | 0.58 | (0.2) | 0.066 |
*p<0.05.
Figure 2Comparison of stroke incidence rates.
The vertebroplasty group had similar incidence rates of any, hemorrhagic and ischemic strokes to that of the comparison group.
Figure 3Cumulative incidence of stroke.
The vertebroplasty group had similar cumulative incidences of (A) any stroke, (B) hemorrhagic stroke, and (C) ischemic stroke as the comparison group from the immediate post-operative period till the end of the five-year follow-up.
Hazard ratios of subsequent strokes post-vertebroplasty (2004.1.1–2008.12.31, n = 1989).
| Stroke during 5-year-follow-up | Comparison group | Vertebroplasty group | (95% CI) |
|
| Any stroke | ||||
| Crude hazard ratio | 1.00 | 1.13 | (0.62–2.04) | 0.693 |
| Adjusted hazard ratio | 1.00 | 1.22 | (0.67–2.24) | 0.518 |
| Hemorrhagic stroke | ||||
| Crude hazard ratio | 1.00 | 2.21 | (0.71–6.86) | 0.170 |
| Adjusted hazard ratio | 1.00 | 3.17 | (0.97–10.3) | 0.055 |
| Ischemic stroke | ||||
| Crude hazard ratio | 1.00 | 0.96 | (0.49–1.91) | 0.90 |
| Adjusted hazard ratio | 1.00 | 0.96 | (0.49–1.91) | 0.91 |
Adjustments were made for demographic characteristics (i.e., age, sex, insurance level, geographic location, and urbanization level), co-morbidities (e.g., hypertension, diabetes, valvular heart disease, arrhythmia, cardiovascular disease and Charlson's co-morbidity index), medications (e.g., aspirin, nitrates, lipid lowering drugs, anti-coagulants, and NSAIDs), and baseline propensity scores.